Basilea Pharmaceutica AG Logo

Basilea Pharmaceutica AG

BSLN | SW

Overview

Corporate Details

ISIN(s):
CH0011432447 (+1 more)
LEI:
391200TTZP8EIPSJ5J20
Country:
Switzerland
Address:
Henric Petri-Strasse 35, 4051 Basel
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Basilea Pharmaceutica is a commercial-stage biopharmaceutical company focused on discovering, developing, and commercializing innovative medicines. The company specializes in treatments for severe and life-threatening bacterial and fungal infections. Its key products are the anti-infective brands Cresemba® (isavuconazole) and Zevtera® (ceftobiprole), which it is establishing as global brands. Founded in 2000 as a spin-off from F. Hoffmann-La Roche, Basilea has a proven track record of advancing drugs from research through clinical development to the market, with the goal of becoming a leading company in the hospital anti-infectives sector.

Social Media

Stop Scraping. Start Analyzing.

You're viewing a fraction of the data available for Basilea Pharmaceutica AG. Get complete, real-time, and AI-ready data via the API the pros use.

Get Instant API & Bulk Data Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-08-19 02:00
Earnings Release
Basilea on track with strong 2025 half-year results
English 19.5 KB
2025-08-19 02:00
Earnings Release
Basilea mit starkem Halbjahresergebnis 2025 auf Kurs
German 21.4 KB
2025-08-14 02:00
M&A Activity
Basilea announces in-licensing of a novel clinical phase 3-ready oral antibiotic
English 11.4 KB
2025-08-14 02:00
M&A Activity
Basilea gibt Einlizenzierung eines neuartigen oralen Antibiotikums bekannt, das…
German 12.9 KB
2025-07-08 02:00
Regulatory News Service
Basilea receives USD 39 million funding under BARDA agreement to continue to ad…
English 11.2 KB
2025-07-08 02:00
Regulatory News Service
Basilea erhält im Rahmen ihrer BARDA-Vereinbarung USD 39 Mio. für die weitere E…
German 13.0 KB
2025-02-18 01:00
Earnings Release
Basilea reports strong 2024 full-year results with significant increase in reve…
English 19.9 KB
2025-02-18 01:00
Earnings Release
Basilea meldet für das Gesamtjahr 2024 ein starkes Ergebnis mit deutlichem Anst…
German 23.1 KB
2024-12-23 01:00
Regulatory News Service
Basilea is awarded additional CARB-X funding to develop new drug candidate from…
English 7.8 KB
2024-12-23 01:00
Regulatory News Service
Basilea erhält zusätzliche CARB-X-Förderung für die Entwicklung eines Medikamen…
German 9.2 KB
2024-12-16 01:00
M&A Activity
Basilea announces agreement with Innoviva Specialty Therapeutics for the commer…
English 9.4 KB
2024-12-16 01:00
M&A Activity
Basilea gibt Vereinbarung mit Innoviva Specialty Therapeutics zur Vermarktung v…
German 11.1 KB
2024-09-19 02:00
Earnings Release
Basilea enters into agreement with BARDA to develop novel antifungals and antib…
English 13.7 KB
2024-09-19 02:00
Earnings Release
Basilea schliesst Vereinbarung mit BARDA zur Entwicklung neuartiger Medikamente…
German 15.7 KB
2024-09-06 02:00
Earnings Release
Strong Cresemba® (isavuconazole) sales performance in Europe triggers USD 25 mi…
English 6.4 KB

Automate Your Workflow. Get a real-time feed of all Basilea Pharmaceutica AG filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Basilea Pharmaceutica AG via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2025-05-21 N/A Executive member Sell None 27,000.00 CHF
2025-04-30 N/A Executive member Sell None 17,600.00 CHF
2025-04-23 N/A Executive member Sell None 57,396.20 CHF
2025-04-23 N/A Non-Executive member Sell None 30,331.00 CHF
2025-04-17 N/A Executive member Sell None 173,479.91 CHF
2025-04-17 N/A Executive member Sell None 118,568.67 CHF
2025-04-17 N/A Executive member Sell None 41,255.63 CHF
2024-10-28 N/A Executive member Sell None 22,500.00 CHF
2024-04-25 N/A Executive member Sell None 79,966.26 CHF
2024-04-24 N/A Executive member Sell None 23,128.70 CHF

Peer Companies

Company Country Ticker View
4BASEBIO PLC Logo
Manufactures GMP-compliant synthetic DNA for advanced therapies, vaccines, and cell/gene therapies.
United Kingdom 4BB
ABINGDON HEALTH PLC Logo
A CDMO for lateral flow rapid tests, providing end-to-end services and its own branded products.
United Kingdom ABDX
ABIONYX Pharma Logo
Biotech developing lipid-based therapies for rare renal and ophthalmological diseases.
France ABNX
AB Science Logo
Develops protein kinase inhibitors for oncology, neuro, and inflammatory diseases.
France AB
AcuCort AB Logo
Develops a rapid oral film for acute allergies, croup, and chemo-induced nausea.
Sweden ACUC
Advicenne Logo
Develops and commercializes therapies for rare renal diseases for patients of all ages.
France ALDVI
AegirBio AB Logo
Makes saliva-based diagnostics accessible for at-home & pro health & drug monitoring.
Sweden AEGIR
Aelis Farma Logo
Developing novel CB1 receptor inhibitors for treating brain and CNS disorders.
France AELIS
AGRONOMICS LIMITED Logo Isle of Man ANIC
ALK-Abelló Logo
Develops allergy immunotherapy (AIT) and emergency treatments for severe allergies.
Denmark ALK